Severe forms of pulmonary arterial hypertension (PAH) are most frequently the 47 consequence of a lumen-obliterating angiopathy. One pathobiological model is, that the 48 initial pulmonary vascular endothelial cell injury and apoptosis is followed by the 49 evolution of phenotypically altered, apoptosis-resistant, proliferating cells and an 50 inflammatory vascular immune response. Although there may be a vasoconstrictive 51 disease component, the increased pulmonary vascular shear stress in established PAH 52 is caused largely by the vascular wall pathology. In this review, we revisit the "quasi-53 malignancy concept" of severe PAH and examine to what extent the hallmarks of PAH 54 can be compared to the hallmarks of cancer. The cancer model of severe PAH, based 55 on the growth of abnormal vascular and bone marrow-derived cells, may enable the 56 emergence of novel cell-based PAH treatment strategies. 57 58 59 60 61 62 Introduction 63 64 "One day, we imagine that cancer biology and treatmentat present a patchwork quilt 65 of cell biology, genetics, histopathology, biochemistry, immunology and pharmacology -66 will become a science with the conceptual structure and logical coherence that rivals that 67 of chemistry and physics." 68 D. Hanahan and RA Weinberg, 2000. 69 70 71 The formal statement of the "quasi-malignancy paradigm of severe pulmonary 72 hypertension" was published in 2008 (138); it had been encouraged by the seminal 73 article, published in 2000 by Hanahan and Weinberg in Cell "The hallmarks of cancer" 74 (65).
153
aspects are also considered in Table  1 154 (137,139,143,152,155,175,178,180,190,193,196,) .
156
The 2008 publication that introduced the concept of "quasi-malignancy" of severe,
Hallmarks of cancer and PAH, the last ten years 220 221
Cell-cell interactions 222 223 Central to the cancer hallmarks theory (66) and likewise central to the PAH hallmarks 224 are the multiple cell-cell interactions.
226
Hanahan and Weinberg have emphasized the importance of the tumor environment, of 227 stromal cells, cancer stem cells and cells of the immune system. As monocellular in vitro 228 cancer studies are of a limited scope, it is doubtful that the investigation of cultured 229 endothelial cells obtained from the lungs of PAH patients, which demonstrate a limited 230 cell growth, can elucidate the cancer paradigm of PAH. While the normal wall of the 231 small pulmonary vessels is complex, with the syncytial relationship between endothelial 232 cells and VSMC, the "sick lung vessels" with their phenotypically changed cells and 233 infiltration by multiple inflammatory cell types is infinitely more complex (174, 182) . There 234 are at least two reasons why cells cultured from PAH vessels do not exhibit unlimited 235 growth. First, it is unclear whether the relevant vascular lesion cells have indeed been 236 harvested and cultured; presently we lack important information regarding the 237 phenotypical characterization of these cells. For example, we do not know whether the 238 cultured EC express 5- LO, FLAP (190) and survivin (138) and lack expression of the 239 PGI2 synthase and of caveolin and PPAR gamma (181). Second, precursor and stem 240 cells (62,63) and factors or co-factors that drive cell proliferation in situ may be missing 241 in a mono-cellular culture environment. Complex, multi-cellular lesions have been found 242 at the sites of small vessel bifurcations, believed to be sites of high shear stress and 243 perhaps turbulent flow (31) . Another explanation regarding the localization of the 244 complex lesions is that the EC at these sites are phenotypically distinct or that the cell 245 proliferation is largely driven by stem cells (48, 172) .
247
Infiltration of immune and inflammatory cells is a hallmark of cancer and plays a critical 248 role in tumorigenesis by creating an inflammatory microenvironment that promotes tumor 249 growth (150). Analogously, PAH is characterized by the perivascular infiltration of innate 250 and adaptive immune cells including mast cells, macrophages, B-and T-cells (21, 88) .
251
Evidence from recent preclinical and epidemiological studies suggest a critical 252 contribution of immunity and its regulation by inflammatory cytokines [in particular IL-6 253 (136)], leukotrienes [LTB 4 and LTC4 (89, 169, 190) 
319
Vascular injury can transform a singular inflammatory event into a chronic 320 inflammatory condition manifested within the pulmonary vascular lesion itself, which 321 becomes a nidus for immunity. A notable illustration of this idea is the acquisition of 322 intimal 5-lipoxygenase (5-LO) expression with the evolution of PAH (190, 197 (5, 16, 18, 43, 134, 196) . Glycolysis is controlled among others by p53, the oncogene cMyc 
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EnMT is one example of the cell phenotype switch and may be the PAH counterpart of 
399
but also cellular senescence and the selection of apoptosis-resistant cells (Figure 3 ).
400
Indeed, DNA damage and chromosomal abnormalities in PAH has been reported 401 (2, 26, 96, 105, 140 
410
NFκB and BRCA1 [the reader is referred to several excellent reviews of the topic of DNA 411 damage and repair (10, 53, 71, 128) ]. Most cancers are associated with p53 mutations.
412
One of the many functions of p53 is the suppression of glycolysis (81) 
449
Anoikis (greek: "homeless") is defined as cell death following the detachment of cells 450 from their matrix. Anoikis-resistance is part of the survival skills of cancers. Interestingly
451
anoikis-resistance can be induced by shear stress (98), STAT3 (100) and β-catenin 452 (95, 124) . We speculate that -in analogy to cancer -the phenotype switch of the cells, 
500
We conclude this discussion of the angiogenesis hallmark of PAH with a word of 512 513 514 515
Bone marrow, stem cells and metastases
517
There is convincing evidence for a bone marrow-lung circulation axis (7, 8 
526
It has been pointed out that one of the Hallmarks of Cancer, 'metastases', is missing in 527 PAH. "In addition to local signaling within the primary tumor environment, tumors also 528 signal over long distances to sites of future metastases to promote the formation of a 529 hospitable pre-metastatic niche that will foster growth of disseminated tumor cells upon 
542
Presently, a complete understanding of bone marrow derived precursor cells,
543
circulating and pulmonary-resident stem cells is lacking. Animal experiments have 544 yielded data that demonstrate that bone marrow cells contribute to the pulmonary 545 vascular disease, but also that hematopoietic stem cells protect against PH (8, 60, 192 
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Summary and Outlook
578
Here we have re-examined the quasi-malignancy concept of severe PAH. Since the 579 publication of the "Cancer paradigm of PAH' article (138) in 2008, many publications 580 provide data that support this concept [ Figure 1 ], including the recently pronounced 581 "epigenomics" hypothesis (113). To summarize: there are robust hallmarks, which are 582 shared between PAH and cancer: the phenotypic switch, the angiogenic switch and the 583 glycolytic switch. On the cellular level, the issue is one of cell survival and cell fate. In
584
PAH too many cells in the vascular wall are surviving and too many cells are abnormal.
586
The last decade has evolved a more nuanced concept of the cancer hallmarks 587 (13, 20, 25, 29, 34, 101, 156, 157, 171) and likewise, investigators in the PH research field 588 continue to refine the hallmarks of PAH (4, 18, 38, 60, 70, 77, 134) . It is likely that advances 589 in genotyping and phenotyping (61,63) will also occur by putting to use liquid biopsies 
598
Are we there yet? We are not, but we are getting closer, we are seeing the light at the 599 end of the tunnel (184). What would novel, successful treatments for severe PAH look 600 like? They would be disease modifying. In our opinion, there are two desirable treatment 601 outcomes: 1) Reversal of the disease in incident cases and 2) halting disease 602 progression and stabilization of cardiac performance. For the second outcome goal there 603 is an example. It has not universally been appreciated that many of the aminorex-604 induced IPAH patients that had been diagnosed in the 1970ies survived without 605 treatment for many years. Their PAH did not disappear, but their disease did not 606 progress.
608
If indeed many forms of angioobliterative PAH are quasi-malignantas we suggest - 998 999 effect] (5, 19, 43, 196) , up-regulation of GLUT1
Cancer stem cells (171) Bone marrow-derived stem cells (7), vessel wall stem cells (48,155), circulating endothelial cell precursors (7, 22) Evasion of immune destruction Immunosuppressive T regs? (163) Deficiency in development or function of cytotoxic CD8+ CD4+ Th1 helper cells Secretion of immunosuppressive TGF-β (66) * This concept relates to a process "formally analogous to a Darwinian evolution, in which a succession of genetic changes, each conferring one or another growth advantage, leads to progressive conversion of normal human cells" (65). ** "Wound healing gone awry" (42), injury to the endothelium is not repaired with a return to a normal endothelial cell monolayer, instead, exuberant endothelial cell growth (174) occurs leading to lumen obliteration and fibrosis. Inflammatory and immune cells participate in this process (174). *** Although metastatic spread turns cancer into a systemic disease, some cancers can remain localized. # Although stem cells in PAH are not "cancer" stem cells, they may nevertheless participate in the formation of complex vascular lesions. 
Characteristics and conditions which do not support a cancer hypothesis of PAH
In PAH there are no metastases to the liver, bone brain or adrenals.
Cells harvested from human PAH lungs do not exhibit unlimited growth* Tumor vessels are leaky, vessels obliterated by proliferating cells are not**.
Driver mutations of KRAS, HRAS, BRAF, BRCA are not implicated in PAH.
There are long-term survivors of severe PAH. *The cells harvested and cultured may not be the relevant vascular lesion cells. See text for more details.
**The initial phase of the PAH lung vessel disease is unknown, whether in early PAH vessels exhibit an increase in permeability is unknown. 
